American Society of Hematology, Blood, 10(132), p. 1050-1063
DOI: 10.1182/blood-2018-03-836601
Full text: Unavailable
Key Points First-in-class MIR17PTi enables 1-shot downregulation of miR-17-92 in vitro and in vivo, with favorable pharmacokinetic profile. MIR17PTi affects homeostatic MYC/miR-17-92 FFLs in MM cells, resulting in strong anti-MM activity.